Abstract
Introduction
Type 2 diabetes mellitus (T2DM) is associated not only with high direct healthcare costs, but also with indirect costs, as diabetic complications and the disease itself result in loss of productivity. Vildagliptin is a novel dipeptidyl peptidase-4 inhibitor that is given either alone or in combination with oral hypoglycemic drugs, including metformin. The study was designed to assess the hypothesis that fixed-combination vildagliptin/metformin improves work productivity measured as Work Productivity and Activity Impairment (WPAI) scores. Secondary objectives were the assessment of patient satisfaction by means of the Diabetes Treatment Satisfaction Questionnaire (DTSQs), the change in anthropometric measurements and in glucose control (glycated hemoglobin [HbA1c]), and the evaluation of resource utilization (Resources Utilization Questionnaire).
Methods
This study was an addendum to a mandatory, prospective, observational study carried out by the Italian Medicines Agency (Agenzia Italiana del Farmaco [AIFA]) in 49 diabetes centers in Italy. The addendum included 1,046 adult outpatients with a diagnosis of T2DM, who were no longer responding to metformin monotherapy. Patients were observed for up to 1 year.
Results
Mean activity impairment improved by 40.6% (15.4 ± 17.4 vs. 26.1 ± 24.4; P < 0.0001), absenteeism by 49.9% (2.0 ± 9.4 vs. 3.8 ± 13.3; P = 0.0076), and total work productivity by 37.6% (14.9 ± 15.9 vs. 21.5 ± 24.6; P < 0.0001). This resulted in a reduction of the annual indirect cost due to impaired productivity of yy400 per working patient and yy135 per patient in general. The DTSQ score increased by 30.2% (29.6 ± 5.6 vs. 22.8 ± 6.9; P < 0.0001). The satisfaction rate increased from baseline by 44.7%; the hyperglycemia-free or almost hyperglycemia-free perception rate by 37.9%; and the hypoglycemia-free or almost hypoglycemia-free rate by 15.2%. Mean healthcare costs per patients diminished by 19.2% in the second semester of treatment.
Conclusion
This observational study suggests that the fixed combination of vildagliptin/ metformin increases work productivity, reducing indirect costs, and improves quality of life, especially in terms of perception of blood glucose variability, in patients with T2DM.
Article PDF
Similar content being viewed by others
References
DM News (Medical Department Bulletin) — December 2012. Data on file. Italy; Novartis Farma S.p.A.; 2010.
Jönsson J. Revealing the cost of type II diabetes in Europe. Diabetologia. 2002;45:S5–S12.
Diabetes fact sheet. Available at: http://www.who.int/mediacentre/factsheets/fs312/en/index.html. Accessed Aug 26 2011.
National Center for Chronic Disease Prevention and Health Promotion. Fact sheet. Diabetesatwork.org. Available at: http://www.cdc.gov/diabetes/pubs/factsheets/atwork.htm. Accessed Jan 15 2013.
Holmes J, Gear E, Bottomley J, Gillam S, Murphy M, Williams R. Do people with type 2 diabetes and their carers lose income? (T2ARDIS-4) Health Policy. 2003;64:291–296.
Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G, The costs of type 2 diabetes mellitus in italy a CODE-2 sub-study. Treat Endocrinol. 2003;2:121–133.
International Diabetes Federation Clinical Guidelines Task Force. Global Guideline for type 2 diabetes. 2005. Available at: http://www.staff.ncl.ac.uk/philip.home/IDF%20GGT2D.pdf. Accessed Jan 15 2013.
UKPDS Study Group. Overview of six years’ therapy of type 2 diabetes, a progressive disease. Diabetes. 1995;44:1249–1258.
Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005–2012.
Dejager S, Baron MA, Schweizer A. Emerging treatments for type 2 diabetes. DPP-4 inhibitors: review of vildagliptin phase 3 data. Rev Endocrinol. 2007;1:47–51.
Ahren B, Foley JE, Bosi E. Clinical evidence and mechanistic basis for vildagliptin’s action when added to metformin. Diabetes Obes Metab. 2011;13:193–203.
Registro farmaci antidiabetici sottoposti a monitoraggio — Rapporto farmaci incretino-mimetici e DPP-4 inibitori. Available at: http://antidiabetici.agenziafarmaco.it/ [In Italian]. Accessed Jan 15 2013.
Eucreas 50 mg/850 mg and 50 mg/1000 mg film-coated tablets. Summary of Product Characteristics. Last updated on the eMC: 09/01/2013. Available at: http://www.medicines.org.uk/emc/medicine/20735/SPC/. Accessed Jan 17 2013.
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of work productivity and activity impairment instrument. PharmacoEconomics. 1993;4:353–365.
Reilly Associates. WPAI Scoring. Available at: http://www.reillyassociates.net/WPAI_Scoring.html. Accessed Jan 15 2013.
Bradley C. The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In: Bradley C, (ed). Handbook of Psychology and Diabetes: a Guide to Psychological Measurement in Diabetes Research and Practice. Chur: Harwood, 1994:111–132.
Hospital care service tariffs for acute cases hospitalized in a ward or in a day hospital unit [in Italian]. Ordinary Supplement of Official Gazette. no 289, 2006.
Specialist care services in clinics disbursed by the National Health Service and relative tariffs. [In Italian]. Available at: http://www.trovanorme.salute.gov.it/dettaglioAtto?id=6403. Accessed Jan 30 2013.
Lucioni C, Mazzi S, Serra G. [L’impatto delle complicanze diabetiche sui costi sanitari e la QoL del paziente con Diabete di Tipo 2: i risultati dello studio CODE-2]. Il Diabete. 2000:275–286. In Italian.
Banca d’Italia — Relazione Annuale sul 2009, 31 maggio 2010. Available at: http://www.bancaditalia.it/pubblicazioni/relann/rel09 [In Italian]. Accessed Jan 17 2013.
Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ. 1995;310:170
Brod M, Christensen T, Thomsen TL, Bushnell DM. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011;14:665–671.
Bosi E, Rochotte E, Camisasca RP, Garber AJ, Collober C. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30:890–895.
Bolli G, Dotta F, Colin L, Minic B, Goodman M. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab. 2009;11:589–595.
Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2009;11:506–515.
Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab. 2011;13:55–64.
Nicolucci A, Cucinotta D, Squatrito S et al. Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis. 2009;19:45–53.
Garattini L, Chiaffarino F, Cornago D, Coscelli C, Parazzini F, Direct medical costs unequivocally related to diabetes in Italian specialized centers, Eur J Health Econom. 2004;5:15–21.
Marchesini G, Forlani G, Rossi E, Berti A, De Rosa M on behalf of the ARNO Working Group. The direct economic cost of pharmacologically-treated diabetes in Italy — 2006. Nutr Metab Cardiovasc Dis. 2011;21:339–346.
Zaniolo O, Sacchi V, Pradelli L. [Impatto sul budget del SSN dell’impiego di vildagliptin, un nuovo ipoglicemizzante orale.] Farmacon Percorsi Terap. 2008;9:137–146. In Italian.
Periodic Safety Update Report 4 (PSUR 4). Period covered: 01 Jan 2009–30 Nov 2009; Periodic Safety Update Report 5 (PSUR 5). Period covered: 01 Dec 2009–30 Nov 2010; PSUR Addendum Report 01. Period covered: 01 Dec 2010–20 Jul 2011. Data on file. Italy; Novartis Farma S.p.A.; 2011.
Di Bonaventura M, Link C, Pollack MF, Wagner JS, Williams SA. The relationship between patient-reported tolerability issues with oral antidiabetic agents and work productivity among patients having type 2 diabetes. J Occup Environ Med. 2011;53:204–210.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is published with open access at Springerlink.com
On behalf of the Investigator’s team
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Genovese, S., Tedeschi, D. Effects of Vildagliptin/Metformin Therapy on Patient-Reported Outcomes: Work Productivity, Patient Satisfaction, and Resource Utilization. Adv Therapy 30, 152–164 (2013). https://doi.org/10.1007/s12325-013-0001-z
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-013-0001-z